Anyone else remember the table from Page 11 of the Investor...

Anyone else remember the table from Page 11 of the Investor Presentation announced 14/3,
at the time Management was trying to convince everyone why they needed to approve the T2 tranche of funding.

They got the money, so where exactly is value being delivered through other clinical programs??

------------------------------------------------------------------------------
If only T1 is approved…
• The first $15 million will be used mainly to advanceAMD and hepatitis B through in vivo pre
clinical studies, and the lung cancer and hepatitis C through to the end of Phase I/IIatrials
• APhase IIbhepatitis C trial will not be possible
• Pain, OPMD, platform technology development and research into other targets will not
be able to be advanced;
• Lung cancer application will be taken through a phase I/IIaclinical trial.

If bothT1 and T2 are approved

• TT‐034 will be able to complete Phase Iibclinical trial in Hepatitis C

• Pending successful trial completion, the program will be significantly more valuable
to Benitec for potential pharmacompany partnering

• AMD and HepatitisB applications will be advanced towards and potentially into clinical
trial stage.

• Pain and OPMD will be progressed;and platform technology development and research
into other applications will commence

"The $31.5 million placement will allow Benitec to complete Phase IIb trials in HCV,
while also delivering value through other clinical programs"